UCONN

HEALTH

Photo of John B. Schenkman, Ph.D.

John B. Schenkman, Ph.D.

Professor, Department of Cell Biology
Academic Office Location:
Cell Biology
UConn Health
263 Farmington Avenue
Farmington, CT 06030-6125
Phone: 860-679-3694
Fax: 860-679-2473
Website(s):

Cell Biology Graduate Program

Schenkman Lab Page

Education
DegreeInstitutionMajor
B.A.Brooklyn CollegeChemistry
Ph.D.State University of New York, Upstate Medical CenterBiochemistry

Post-Graduate Training
TrainingInstitutionSpecialty
PostdoctoralJohnson Research Foundation, University of Pennsylvaniaa) Studies on mechanism of action of cytochrome P450 monooxygenases b) Role of orthologous cytochromes P450 in tissue development c) Development of screens for identification of tissue-selective carcinogen identification.

Awards
Name of Award/HonorAwarding Organization
Travel Awardee to BritainWellcome Research
Awardee, Japan Soc. for Promotion of Science
Travel Awardee to BritainWellcome Research
Travel Awardee to Britain Wellcome Research
Career Development Awardee National Institutes of Health
Career Development Awardee National Institutes of Health
Career Development Awardee National Institutes of Health
Career Development Awardee National Institutes of Health
Career Development Awardee National Institutes of Health
Career Development Awardee National Institutes of Health
Visiting Scientist Awardee to JapanNational Science Foundation
Name & DescriptionCategoryRoleTypeScopeStart YearEnd Year
American Society for Pharmacology and Experimental Therapeutics: Member Drug Metabolism DivisionProfessional/Scientific OrganizationElected Counselor ExternalNational19951998
Association of Medical School PharmacologistsProfessional/Scientific OrganizationCouncilorExternalNational19871989
British Biochemical Society Professional/Scientific OrganizationMemberExternalInternational1971
American Society for Biochemistry and Molecular Biology Professional/Scientific OrganizationMemberExternalNational1971
American Society for Pharmacology and Experimental TherapeuticsProfessional/Scientific OrganizationMemberExternalNational1969
The cytochrome P450s are ubiquitous proteins found in most phyla. Several thousand different forms have already been identified. The individual species have large numbers of cytochrome P450 forms. In humans, for example, 57 different forms of cytochrome P450 have been identified in the genome. The mouse genome contains 93 different forms. The different forms of cytochrome P450 can be grouped into families, based upon amino acid sequence identity. In mammals, families 1-3 are generally considered as 'xenobiotic-metabolizing' enzymes, oxidizing the greatest number of drugs and chemicals encountered in the environment, as well as a number of endobiotics like steroids destined for excretion or used in intermediary metabolism of compounds necessary for homeostasis. Most of the families of cytochrome P450 are involved, in one way or another, in steroidogenesis, vitamin metabolism or maintenance of homeostasis in the body. In recent studies, however, it has become apparent that a number of the xenobiotic metabolizing cytochrome P450s are present in the conceptus and the developing embryo and fetus at specific times after conception (Choudhary et al., 2004a; Choudhary et al., 2003; Choudhary et al., 2005), appearing to function as development-influencing gene products (Schenkman et al., 2003).

Mutations in the cytochrome P450 1B1 (CYP1B1) gene in humans results in the disease, Primary Congenital Glaucoma (PCG), which appears to be due to abnormal development of the trabecular meshwork at the angle of the eye. Although the mouse does not develop the same disease phenotype, damage to the mouse orthologous gene does result in similar histologically observed abnormal development of the trabecular meshwork. We have shown that point mutations in the human gene, which in patients cause PCG, result in forms of CYP1B1 that are expressed as a holoenzyme, with lesser stability and lower specific activity toward endobiotics (Choudhary et al., 2004b; Jansson et al., 2001). We have used the mouse to examine the temporal and spatial appearance of Cyp1b1 (the mouse ortholog) protein in mouse eye structures by histological and immunohistological methods (Choudhary et al., 2006) in order to gain an understanding of how the absence of a fully active form of the enzyme might result in the PCG phenotype. We note that, "the distinctive constitutive expression pattern of some CYPs during mouse ontogeny and their presence in human fetal tissues suggests an involvement in morphogenesis and patterning of different embryonic structures. This might occur by modulating the level of ligands required for activation of membrane or nuclear receptors", and it was suggested that such ligands were probably endobiotics of lipophilic properties (Choudhary et al., 2006). Examination of the effects of four different PCG-causing mutations of CYP1B1 on the stability and catalytic activities revealed impairment of these characteristics by the mutations, strongly suggestion diminution of function in the absence of enhanced levels of the enzyme are the cause of the observed PCG phenotype (Choudhary et al., 2008). Toward this observation, it was suggested that CYP1B1 might eventually serve as a potential target for gene therapy of the PCG condition (Choudhary et al., 2009).

Metabolism of different chemicals by cytochrome P450 forms often results in their conversion into active electrophiles that can react with DNA. It is generally accepted that such reactions are the cause of different cancers. In other studies we have been examining the ability to make use of cytochrome P450 forms in electrochemical analysis of the potential of different drugs and environmental pollutants to cause genotoxic effects by virtue of reacting with the DNA in thin films (Estavillo et al., 2003; Munge et al., 2003; Rusling et al., 2008; Zhou et al., 2003). Using microsomes containing cytochrome P450 and cytochrome P450 reductase (CPR) we have been able to show the involvement of CPR in the electrochemical activation of these environmental pollutants by cytochrome P450 forms (Sultana et al., 2005; Sultana et al., 2007). In attempts to make rapid throughput of analyses, arrays have been developed in which multiple forms of activating enzyme could be inserted to take advantage of differences in substrate specificities (Wang et al., 2005). Using the electrochemical method and layer-by-layer formation of interacting cytochrome P450 system components and DNA it could be shown that reactive intermediates were formed which could complex with and damage the DNA (Krishnan et al., 2007; So et al., 2008; So et al., 2007). Arrays for the electrochemical activation of the carcinogen benzo(a)pyrene by multiple forms of cytochrome P450 were developed (Hvastkovs et al., 2007). One could also use microsomes containing mixtures of metabolic enzymes in thin films with DNA for screening compounds for genotoxicity (Krishnan et al., 2008), or pure enzymes, developing methods for screening the DNA (Bajrami et al., 2008; Fundador et al., 2008). We have been monitoring DNA reactivity with different potential toxicants (Bajrami et al., 2009; Hull et al., 2009; Krishnan et al., 2009; Zhao et al., 2009a; Zhao et al., 2009b).

Not accepting students for Lab Rotations at this time

Journal Articles

Books

  • Hepatic Cytochrome P450 Monooxygenase System
  • Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds

Book Chapters

  • Cytochrome P450 2S1 depletion enhances cell proliferation and migration in bronchial epithelial cells, in part, through modulation of prostaglandin E(2) synthesis.
    Madanayake, T W; Fidler, T P; Fresquez, T M; Bajaj, N; Rowland, A M Drug metabolism and disposition: the biological fate of chemicals 2012 Nov;40(11):2119-25
  • Genetics and biochemistry of primary congenital glaucoma.
    Sarfarazi, Mansoor; Stoilov, Ivaylo; Schenkman, John B Ophthalmology clinics of North America 2003 Dec;16(4):543-54, vi
  • Age and sex differences in constitutive forms of cytochrome P-450 of rat liver microsomes.
    Schenkman, J B; Favreau, L V; Jansson, I Advances in experimental medicine and biology 1986 Jan;197107-17
  • Possible mechanism of coupled NADPH oxidase and P-450 monooxygenase action.
    Jansson, I; Schenkman, J B Advances in experimental medicine and biology 1981 Jan;136 Pt A145-63
  • A Brief History of Cytochrome P-450
    J.B. Schenkman Hepatic Cytochrome P-450 Monooxygenase System 1-5
  • Aryl Hydrocarbon Hydroxylase: Induction
    J.B. Schenkman, K.M. Robie-Suh and I. Jansson Biological Reactive Intermediates: Formation, Toxicity and Inactivation 83-97
  • Basic Mechanism of Drug Interactions
    J.B. Schenkman Drug Interactions, Continuing Education in Pharmacy 1-21
  • Compositional Changes in Sexually Differentiated forms of Hepatic Cytochrome P-450 in the Diabetic Rat
    K.E. Thummel, S.M. Hopfer and J.B. Schenkman Highlights of Modern Biochemistry 247-256
  • Cytochrome P-450 and Mixed Function Oxidations
    R.W. Estabrook, J.B. Schenkman, W. Cammer, H. Remmer, D.Y. Cooper, S. Narasimhulu, and O. Rosenthal Biological and Chemical Aspects of Oxygenases 153-170
  • Cytochrome P450: Historical Overview
    J. B. Schenkman Metabolic Drug Interactions 51-60
  • Cytochrome P-450-Dependent Monooxygenase: An overview
    J.B. Schenkman Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds 1-10
  • Functional Aspects of Protein-Protein Interactions of Cytochrome P-450 Cytochrome B5 and Cytochrome P-450 Reductase
    J.B. Schenkman Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds 185-198
  • High-Throughput Enzyme Biocolloid Systems for Drug Metabolism and Genotoxicity Profiling Using LC-MS/MS
    J.F. Rusling and J.B. Schenkman High-Throughput Screening Methods in Toxicity Testing
  • Historical Background and Description of the P-450 Monooxygenase System
    J.B. Schenkman Cytochrome P-450 3-13
  • Homeostatic Changes in Hepatic Microsomal Cytochrome P-450
    J.B. Schenkman, K.E. Thummel and L.V. Favreau Cytochrome P-450: Biochemistry and Biophysics 851-854
  • Induction of Microsomal Liver Enzymes
    H. Remmer, R.W. Estabrook, J.B. Schenkman and H. Greim Enzymatic Oxidations of Toxicants 65-85
  • Influence of Substrates of Hepatic Mixed Function Oxidases on Spin Equilibrium of Cytochrome P-450
    I. Jansson, G.G. Gibson, S.G. Sligar, D.L. Cinti and J.B. Schenkman Microsomes, Drug Oxidations and Chemical Carcinogenesis 139-142
  • Interaction Between Cytochrome P450 and Reductase
    J.B. Schenkman and A.I. Voznesensky NATO ASI Series H, Vol. 90, Molecular Aspects of Oxidative Drug-Metabolizing Enzymes 47-63
  • Interaction between NADPH-cytochrome P-450 Reductase and Cytochrome P-450 CYP2B4
    J.B. Schenkman, A.I. Voznesensky and A.I. Archakov Cytochrome P-450: Biochemistry and Biophysics 240-247
  • Interactions Between Cytochrome P-450 and other Components of the Microsomal Electron Transfer Systems
    J.B. Schenkman, P.P. Tamburini, I. Jansson and P.M. Epstein Yamada Conference XVII Cytochrome P-450: New Trends 59-63
  • Introduction to Cytochrome P450
    J.B. Schenkman and I. Jansson NATO ASI Series H, Vol. 90, Molecular aspects of Oxidative Drug Metabolizing Enzymes 1-19
  • Isolation and Purification of Constitutive Forms of Microsomal Cytochrome P450
    J.B.Schenkman and I. Jansson Cytochrome P450 Protocols, Methods in Molecular Biology 55-67
  • Measurement of Cytochrome P450
    J.B. Schenkman and I. Jansson Current Protocols in Toxicology 4.1.1-4.1.14
  • Methods for the Evaluation of Hepatic Microsomal Mixed Function. Oxidase Levels and Cytochrome P-450
    H. Remmer, H. Greim, J.B. Schenkman and R.W. Estabrook Methods in Enzymology 703-708
  • Microsomal Biotransformation System in Cholestasis
    F. Hutterer, H. Greim, D. Trulzsch, P. Czygan and J.B. Schenkman Progress in Liver Diseases
  • On the Nature of the NADPH-Cytochrome P450 Reductase-Cytochrome P450 Electron Transfer Complex
    A.I. Voznesensky and J.B. Schenkman Cytochrome P450: Biochemistry, Biophysics and Molecular Biology 349-356
  • On the Significance of Drug-Induced Spectral Changes in Liver Microsomes
    S. Orrenius, B.J. Wilson, C. von Bahr and J.B. Schenkman Biological Hydroxylation Mechanism 55-78
  • Phase I Biotransformation Reactions: Cytochrome b5
    J.B. Schenkman and I. Jansson xPharm
  • Physiological and Pathophysical Alterations in Rat Hepatic Cytochrome P-450
    J.B. Schenkman, K.E. Thummel and L.V. Favreau Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds 233-253
  • Preparation of Microsomes with Calcium
    J.B. Schenkman and D.L. Cinti Methods in Enzymology 83-88
  • Protein-Protein Interactions
    J.B. Schenkman Cytochrome P-450 527-545
  • Protein-Protein Interactions in the P450 Monooxygenase System
    J.B. Schenkman, I. Jansson, G. Davis, P.P. Tamburini, Z. Lu, A. Zhang, and J.F. Rusling NATO ASI Series H, Vol. 303, Molecular and Applied Aspects of Oxidative Drug Metabolizing Enzymes 21-39
  • Screening for Reactive Metabgolites Using Genotoxicity Arrays and Enzyme/DNA Biocoloids
    J.F. Rusling, E.G. Hvastkovs and J.B. Schenkman Drug Metabolism Handbook: Concepts and Applications 307-340
  • Similarities and Differences in Properties Between Constitutive forms of Cytochrome P-450
    J.B. Schenkman, L.V. Favreau, I. Jansson and J.E. Mole Drug Metabolism from Molecules to Man 1-13
  • Spectral Analyses of Cytochrome P450
    J.B.Schenkman and I. Jansson Cytochrome P450 Protocols, Methods in Molecular Biology 25-33
  • Spectral Analyses of Cytochromes P450
    J.B. Schenkman, and I. Jansson Methods in Molecular Biology 11-18
  • Spectral Investigations on Cytochrome P-450
    H. Remmer, J.B. Schenkman and H. Greim Microsomes and Drug Oxidations 371-385
  • Spin States and Redox Potentials of Hepatic Cytochrome P-450
    S.G. Sligar, D.L. Cinti, G.G. Gibson and J.B. Schenkman Microsomes, Drug Oxidations and Chemical Carcinogenesis 175-178
  • Status of the Cytochrome P-450 Cycle
    J.B. Schenkman and G.G. Gibson Drug Metabolism and Distribution, Current Reviews in Biomedicine 3 7-11
  • Studies on Two Constitutive Isozymes of Rat Liver Microsomal Cytochrome P-450
    J.B. Schenkman and K.C. Cheng Microsomes, Drug Oxidations and Drug Toxicity 95-100
  • Substrate Interaction with Cytochrome P-450
    J.B. Schenkman, S.G. Sligar and D.L. Cinti Hepatic Cytochrome P-450 Monooxygenase System 587-615
  • The Fate of Xenobiotics in the Body; Enzymes of Metabolism
    J.B. Schenkman NATO ASI Series H, Vol. 303, Molecular and Applied Aspects of Oxidative Drug Metabolizing Enzymes 1-20
  • The Influence of Fatty Acids and Membrane Lipids on the Spin State of Purified Cytochrome P-450
    G.G. Gibson, S.G. Sligar, D.L. Cinti and J.B. Schenkman Microsomes, Drug Oxidations and Chemical Carcinogenesis 119-122
  • The Role of Cytochrome P-450 in Microsomal Mixed Function Oxidase Reactions
    R.W. Estabrook, A. Hildebrandt, H. Remmer, J.B. Schenkman, O. Rosenthal and D.Y. Cooper Biochemie des Sauerstoffs 142-156

Abstracts

  • Identification of novel mutations causing familial primary congenital glaucoma in Indian pedigrees.
    Panicker, Shirly G; Reddy, Aramati B M; Mandal, Anil K; Ahmed, Niyaz; Nagarajaram, Hampapathalu A; Hasnain, Seyed E; Balasubramanian, Dorairajan Investigative ophthalmology & visual science 2002 May;43(5):1358-66
  • Paradoxical effect of Sudan III on the in vivo and in vitro genotoxicity elicited by 7,12-dimethylbenz(a)anthracene.
    Hatakeyama, S; Hayasaki, Y; Masuda, M; Kazusaka, A; Fujita, S Journal of biochemical toxicology 1995 Jun;10(3):143-9
  • Microsomal proteins and hemoproteins: enhancement of phenobarbital induction by prevention of breakdown due to starvation.
    Greim, H Chemico-biological interactions 1971 Aug;3(4):271-3
  • A Glycerophosphate Dehydrogenase Response
    J.B. Schenkman, D.A. Richert and W.W. Westerfeld Fed. Proc 23433
  • Active Oxygen in Hepatic Microsomes
    J.B. Schenkman and G. Powis The Pharmacologist 18119
  • Active Oxygen in Liver Microsomal Oxidation of Epinephrine to Adrenochrome
    J.B. Schenkman and I. Jansson Fed. Proc 37464
  • Biomolecular Films with Electrochemical and Enzyme Activity Constructed Layer-by-Layer
    J.F. Rusling, B. Munge, J.B. Schenkman and Y.M. Lvov 219th ACS Meeting, Abs. Coll 461
  • Catalase Inhibition of Microsomal Lipid Peroxidation is Unrelated to its Catalatic Activity
    R.A. Jordan and J.B. Schenkman Fed. Proc. 42877
  • Catalase Inhibition of NADPH-Dependent Microsomal Lipid Peroxidation
    R.A. Jordan and J.B. Schenkman Fed. Proc. 411566
  • Chemical Characterization of Electron Transfer Reactions Involving Different Binding Domains on NADPH Cytochrome P-450 Reductase
    P.P. Tamburini and J.B. Schenkman Fed. Proc. 451747
  • Comparative Expression Profiling of the Mouse Cytochrome P450 Gene Family
    I.R. Stoilov, D. Choudhary, I. Jansson, J. Schenkman, and M. Sarfarazi Am. J. Hum. Genet 71A242
  • Cytochrome P-450 Epitope Typing in Animals and Humans with Monoclonal Antibodies to Ethanol-Induced Rat Liver Microsomal Cytochrome P-450 (P-450et)
    S.S. Park, I.Y. Ko, C. Yang, F.G. Guengerich, J.B. Schenkman, M.J. Coon and H.V. Gelboin Fed. Proc. 451509
  • Cytochrome P-450 in Perfused Liver Slices of the Adult Male Rat
    D.L. Cinti and J.B. Schenkman Fed. Proc. 29346
  • Cytochrome P-450 of Human Liver Microsomes
    J.B. Schenkman, H.L. Gurtoo, T. Dondero and D.G. Johns J. Clin. Invest 4874A
  • Description and Evaluation of a Method for Rapid Preparation of Liver Microsomes
    J.B. Schenkman and D.L. Cinti Abstr. 5th Int. Cong. Pharmacol. 203
  • Direct Electrochemistry of Enzymes in Layer-by-Layer Polyion Films with DNA and Other Polyelectrolytes
    Y. M. Lvov, Z. Lu, J.F. Rusling and J.B. Schenkman PITTCON’98 408
  • Direct Voltammetry of Putidaredoxin in Alternate Polyion Layer-by Layer Films on Gold Electrodes
    Z. Lu, J. Kong, Y. Lvov, J.F. Rusling and J.B. Schenkman PITTCON’98 047
  • Drug Interaction with Hepatic Microsomal Cytochrome
    J.B. Schenkman and H. Remmer Fed. Proc 25343
  • Effects of In Vivo Stress Conditions on Three Related Liver Microsomal Systems
    I. Jansson and J.B. Schenkman Fed. Proc. 34619
  • Effects of Streptozotocin on Constitutive Cytochrome P-450 levels in Sprague-Dawley Rates
    L.V. Favreau and J.B. Schenkman Fed. Proc. 45931
  • Electron Transfer Between NADPH-Cytochrome P-450 Reductase (RED) and Cytochrome P-450 (CYP2B4) does not Involve Complementary Charge Pairing
    A.I. Vozensensky and J.B. Schenkman The FASEB Journal 61839A
  • Explanation of NADH Synergism of NADPH Dependent Hepatic Mixed Function Oxidase (MFO)
    I. Jansson and J.B. Schenkman Fed. Proc. 391811
  • Expression and Functional Characterization of Wild Type and PCG Mutant Forms of CYP1B1
    I. Stoilov, I. Jansson, J. Schenkman, and M. Sarfarazi Invest. Ophthal. & Vis. Sci. 414
  • Feminization of Hepatic Cytochrome P-450s in the Diabetic Rat
    K.E. Thummel, L.V. Favreau, J. Mole and J.B. Schenkman FASEB J 21340
  • Films for Electrode-Driven Catalysis with Heme Enzymes
    J.F. Rusling, X. Zu, Z. Lu, B. Munge, Z. Zhang, N. Hu, H. Ma, and J.B. Schenkman 219th ACS Meeting, Abs 446
  • Functional Interaction Between Cytochrome P 450 2B4 is not by Electrostatic Mechanisms
    J.B. Schenkman and A.I. Voznesensky Pharmacologist 34182
  • Hepatic Microsomal Mixed Function Oxidase
    J.B. Schenkman Science 168612-613
  • Hepatic Organelle Interactions During Drug Biotransformation
    D.L. Cinti and J.B. Schenkman Fed. Proc 31482
  • Hepatocyte Organelle Interaction
    J.B. Schenkman and D.L. Cinti The Pharmacologist 12298
  • High Yield Purification of P-450’s by Affinity Chromatography
    G.G. Gibson and J.B. Schenkman Fed. Proc. 36959
  • Human Cytochrome P450 1B1: Expression in E. coli and report of 21 New Mutations in Subjects with Primary Congenital Glaucoma
    I. Stoilov, I. Jansson, J. Schenkman, and M. Sarfarazi Am. J. Hum. Genet
  • Immunochemical Detection of Rat Hepatic Cytochrome P-450 Changes in Streptozotocin-Induced Diabetes: Time Course and Insulin Reversal
    L. Favreau and J. Schenkman Fed. Proc. 462050
  • Induction of a Low Spin P-450 Species with Pregnenolone 16 Alpha-Carbonitrile (PCN)
    R.E. Talcott and J.B. Schenkman Fed. Proc 34729
  • Influence of Cytochrome B5 on the Stoichiometry of Purified Reconstituted Microsomal P-450
    I. Jansson and J.B. Schenkman Fed. Proc. 451747
  • Influence of Substrates of Different Electron Transfer Pathways on the Oxidation-Reduction Kinetics of Microsomal Cytochrome B5
    I. Jansson and J.B. Schenkman The Pharmacologist 19233
  • Influence of Substrates of Hepatic Mixed Function Oxidases on Spin Equilibrium of Cytochrome P-450
    I. Jansson, G.G. Gibson, S. Sligar, D.L. Cinti and J.B. Schenkman Fed. Proc. 38526
  • Interaction Between Microsomal Electron Transfer Pathways
    I. Jansson and J.B. Schenkman Fed. Proc. 331460
  • Interaction of Cytochrome b5 with Active Oxygen
    I. Jansson and J.B. Schenkman Fed. Proc. 411425
  • Interactions of Proteins of the Cytochrome P450 Monooxygenase System
    J.B. Schenkman, A.I. Voznesensky and I. Jansson FASEB J 8A1240
  • Kinetics of Benzopyrene and 3-Hydroxy Benzopyrene Metabolism in Rat Liver Microsomes
    J.B. Schenkman, K.M. Robie, R.E. Talcott and Y.N. Cha Sixth International Congress of Pharmacology 382
  • Lipid Controls the Spin Equilibrium of Liver Microsomal Cytochrome P-450
    G.G. Gibson, D.L. Cinti, J.B. Schenkman and S.G. Sligar Fed. Proc. 38320
  • Metabolism of Steroid Hormones by Two Purified Cytochrome P-450 Isozymes from Liver Microsomes of Untreated Rats
    K.-C. Cheng and J.B. Schenkman Fed. Proc. 421141
  • Modulation of Hepatic Cytochrome P-450 Oxidation Reduction Equilbria by Substrates and Lipids
    S.G. Sligar, D.L. Cinti, G. Gibson and J.B. Schenkman Fed. Proc. 38320
  • Molecular Basis for Reduced Penetrance in Primary Congenital Glaucoma
    I. Stoilov, I. Jansson, J. Schenkman, and M. Sarfarazi Am. J. Hum. Genet 69A654
  • Nicotinamide Inhibition of Hepatic Microsomal Mixed Function Oxidase
    J.B. Schenkman and R.W. Estabrook Fed. Proc 26729
  • Non-Esterified Fatty Acids in Type II Diabetes and Obesity: Reevaluation using a Specific Chromatographic Assay
    C. Malchoff, L. Kosowicz, H. Davis, D. Malchoff, J. Schenkman, C. Asplin and S. Pohl Clin. Res. 34880A
  • On the Significance of Drug Induced Spectral Changes in Liver Microsomes
    S. Orrenius, B. Wilson, C. von Bahr and J.B. Schenkman Biochem. J. 125
  • Organelle Interactions. Role of Succinate in the Stimulation of Microsomal N-Demethylations
    D.L. Cinti, H. Denk and J.B. Schenkman The Pharmacologist 17216
  • Oxidation of Arachidonate by Rat Liver
    H.W. Davis, T. Suzuki and J.B. Schenkman Fed. Proc 45870
  • Purification and Characterization of Cytochrome P-450 RLM5a from Male Rats
    L.V. Favreau and J.B. Schenkman Fed. Proc. 441208
  • Purification and Characterization of Two Constitutive Forms of Cytochrome P-450
    K.-C. Cheng and J.B. Schenkman Fed. Proc. 411729
  • Rate Limiting Steps in Drug Metabolism
    J.B. Schenkman Chem. Biol. Interactions 3306-307
  • Reaktion von Arznelmitteln mit mikrosomalen cytochromen
    H. Remmer, J.B. Schenkman and R.W. Estabrook Arch. Pharmak. Expetl. Pathol 25562
  • Relationship Between Iron-Dependent NADPH Supported Malondialdehyde Production and Arachidonic Acid Content in Liver Microsomes
    R.A. Jordan and J.B. Schenkman Fed. Proc. 40926
  • Spectral Studies of Drug Interaction with Hepatic Microsomal Cytochrome
    J.B. Schenkman Mol. Pharmacol. 3113-123
  • Spin State Control of Cytochrome P-450 Reduction
    J.B. Schenkman, W.L. Backes and S.G. Sligar Fed. Proc. 40708
  • Spin State Control of Cytochrome P-450 Reduction - Observation of the Charge Transfer Band
    W.L. Backes, S.G. Sligar and J.B. Schenkman Fed. Proc. 411405
  • Studies of Halothane-Cytochrome P 450 Complex and Metabolite Formation in a Purified P-450 System
    R. van Dyke, M. Baker, I. Jansson and J.B. Schenkman Fed. Proc. 441468
  • Studies of the Role of Cytochrome B5 in Cytochrome Pmediated Monooxygenations
    J.B. Schenkman Keio J. Med 3947
  • Studies on Low Spin P-450 Induced by Pregnenolone 16a-Carbonitrile (PCN)
    J.B. Schenkman and R.E. Talcott The Pharmacologist 17186
  • Studies on the Mechanism of NADH Synergism of NADPH Dependent Hepatic Mixed Function Oxidation (MFO)
    J.B. Schenkman and I. Jansson Fed. Proc. 39666
  • Substrate Interaction with Hepatic Microsomal Drug Oxidase: Studies on the Absolute Spectrum
    J.B. Schenkman Fed. Proc 28483
  • Temperature-Induced Spin State Change of Liver Microsomal Cytochrome P-450 from Control, Phenobarbital (PB)- and 3-Methylcholanthrene (MC)-Treated Rats
    D.L. Cinti, G.G. Gibson, J.B. Schenkman and S. Sligar Fed. Proc. 38526
  • The Effect of Urethan on Nascent Protein Synthesis and Mixed Function Oxidase Activities in Normal and Partially Hepatectomized Rats
    R.I. Glazer, D.L. Cinti, R.I. Murahata, J.B. Schenkman and A.C. Sartorelli. Fed. Proc. 31582
  • The Effect of Variation of NADPH-Cytochrome P-450 Reductase Concentration on the Reduction Kinetics of Cytochrome P-450
    W.L. Backes and J.B. Schenkman Fed. Proc. 421902
  • The Influence of Spin State on the Reduction of Cytochrome P-450
    W.L. Backes and J.B. Schenkman Fed. Proc. 401639
  • The Manner of Interaction Between Cytochrome P-450 2B4 and NADPH-Cytochrome P-450 Reductase
    J.B. Schenkman and A.I. Voznesensky J. Basic & Clinical Physiology and Pharmacology 13121
  • The Mouse CYP1 Genes Appear at Different Temporal Points in Development Indicating that Cyp1a1 and Cyp1a2 can not Compensate for the Deficiency of the Congenital Glaucoma Gene Cyp1b1
    I. Stoilov, D. Choudhary, I. Jansson, J. Schenkman, and M. Sarfarazi Inves. Ophthal. & Vis. Sci.
  • Turnover of Heme and Protein Moieties of Purified Rat Liver Hemoproteins
    Y.N. Cha, R.I. Glazer and J.B. Schenkman Fed. Proc. 31548
  • Use of Quartz Crystal Microbalance (QCM) Resonators for the Study of Interactions Between Cytochrome P450 Redox Components
    J.B. Schenkman, I. Jansson, S. Boussard, N. Tao, Y. Lvov, and J.F., Rusling 219th ACS Meeting, Abs. INOR 445

Conference Papers

Newsletters

  • Reminiscences on a Career of P450 Research
    J.B. Schenkman Drug Metab. Newsletter 25(2):1-3

Other

Reviews

Title or AbstractTypeSponsor/EventDate/YearLocation
Bioelectrochemistry and Biological Electron Transfer SymposiumLectureAmerican Chemical Society Meeting2000San Francisco, California
Microsomes, Drug Oxidation, and Clinical PharmacologyLecture1997Berlin, Germany
Is There a Real Risk to Human Health?LectureChilean Biological Society Meeting Symposium1994Puyehue, Chile
Chemistry of P-450 LectureAll Union Conference 1989Yalta, USSR
Chemistry and Physics of Cytochrome P-450LectureYamada Conference on Cytochrome P-4501987Nara, Japan
Cytochrome P-450 and EnvironmentLecture1987Novosibirsk, USSR
Biological Reactive IntermediatesLecture1985College Park, Maryland
Comparative BiochemistryLecture1985Beerse, Belgium
Biophysics and Induction of Cytochrome P-450Plenary Lecture1985Budapest, Hungary
Contributions of Toxicology to Risk Assessment and Health Regulation Lecture1985Tübingen, Germany
Microsomes and Drug OxidationsLecture1981Tokyo, Japan
Biological Reactive IntermediatesLecture1980Surrey, Guilford, Britain
Microsomes and Drug OxidationsLecture1979Ann Arbor, Michigan
Function of Microsomal Drug Metabolizing EnzymesLectureStanford University1972Stanford, California